Reversible pulmonary hypertension in heart transplant candidates - Pretransplant evaluation and outcome after orthotopic heart transplantation

European Journal of Heart Failure

Volumn 5, Issue 5, 2003, Pages 645-653

  Klotz, Stefan ^a   Deng, Mario C ^a,b   Hanafy, Dudy ^a   Schmid, Christof ^a   Stypmann, Jörg ^a   Schmidt, Christoph ^a   Hammel, Dieter ^a   Scheld, Hans H ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Orthotopic heart transplantation; Prostaglandin; Pulmonary hypertension

Indexed keywords

ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ILOPROST; PROSTACYCLIN DERIVATIVE; PROSTAGLANDIN E1; VASODILATOR AGENT;

ADULT; ARTICLE; CASE CONTROL STUDY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EVALUATION; FEMALE; FLUSHING; HEADACHE; HEART CATHETERIZATION; HEART TRANSPLANTATION; HUMAN; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NAUSEA; ORTHOTOPIC TRANSPLANTATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SIDE EFFECT; STATISTICAL ANALYSIS; SURVIVAL; TREATMENT OUTCOME; VOMITING;

ALPROSTADIL; CASE-CONTROL STUDIES; FEMALE; HEART CATHETERIZATION; HEART FAILURE, CONGESTIVE; HEART TRANSPLANTATION; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 0346730902     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-9842(03)00059-X     Document Type: Article

References (41)

1. Chen JM, Levin HR, Michler RM, et al. Reevaluating the significance of pulmonary hypertension before cardiac transplantation: determination of optimal thresholds and quantification of the effect of reversibility on perioperative mortality. J Thorac Cardiov Sur 1997;114:627-34.
2. Costard-Jäckle A, Fowler MB. Influence of perioperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining high risk group. J Am Coll Cardiol 1992;19:48-54.
3. Erickson KW, Costanzo-Nordin MR, O'Sullivan EJ, et al. Influence of preoperative transpulmonary gradient on late mortality after orthotopic heart transplantation. J Heart Transplant 1990;9:526-37.
4. Espinoza NC, Manito N, Roca J, et al. Reversibility of pulmonary hypertension in patients evaluated for orthotopic heart transplantation: importance in the postoperative morbidity and mortality. Transplant Proc 1999;31:2503-4.
5. 1 in the pretransplantation evaluation of heart failure patients with significant pulmonary hypertension. J Heart Lung Transplant 1992;11:716-23.
6. Murali S, Kormos RL, Uretsky BF, et al. Preoperative pulmonary hemodynamics and early mortality after orthotopic cardiac transplantation: the Pittsburgh experience. Am Heart J 1993;126:869-904.
7. Delegado JF, Gomez-Sanchez MA, Saenz de la Calzada C, et al. Impact of mild pulmonary hypertension on mortality and pulmonary artery pressure profile after heart transplantation. J Heart Lung Transplant 2001;20(9):942-8.
8. Deng MC, Gradaus R, Hammel D, et al. Heart transplant candidates at high risk can be identified at the time of initial evaluation. Transplant Int 1996;9:38-45.
9. Barnard CN, Wolpowitz A. Heterotopic versus orthotopic heart transplantation. Transplant Proc 1979;11:309-12.
10. Deiwick M, Hamann PA, Weyand M, et al. Heterotope Herz-transplantation-eine Alternative in der Therapie der terminalen Herzinsuffizienz. Tx Med 1994;6:262-9.
11. Desruennes M, Muneretto C, Gandjbakhch I, et al. Heterotopic heart transplantation: current status in 1988. J Heart Transplant 1989;8:479-85.
12. Simonsen S, Mølstad P, Geiran O, Froysaker T. Heart transplantation in patients with severe pulmonary hypertension and increased pulmonary vascular resistance. Scand J Thorac Card Surg 1990;24:161-4.
13. 1 versus prostacyclin versus dobutamine. J Heart Lung Transplant 1999;18:358-66.
14. 2 (Prostacyclin). Z Kardiol 1999;88:133-40.
15. Pamboukian SV, Carere RG, Webb JG, et al. The use of milrinone in pretransplant assessment of patients with congestive heart failure and pulmonary hypertension. J Heart Lung Transplant 1999;18:367-71.
16. Pascual JMS, Fiorelli AI, Bellotti GM, Stolf NAG, Jatene AD. Prostacyclin in the management of pulmonary hypertension after heart transplantation. J Heart Transplant 1990;9:644-51.
17. 1 for treatment of elevated pulmonary resistance in patients undergoing cardiac transplantation. Transplant Proc 1989;21:2555-6.
18. Zink M, Gombotz H, Wasler A, Grasser B, Rehak P, Metzler H. Urapidil reduces elevated pulmonary vascular resistance in patients before heart transplantation. J Heart Lung Transplant 2002;21:347-53.
19. Piper PJ, Vane JR, Wyllie JH. Inactivating of prostaglandins by the lungs. Nature 1970;225:600-4.
20. Deng MC, Breithardt G, Scheld HH. Interdisciplinary heart failure and transplant program Münster: a 5-year experience. Int J Cardiol 1995;50:7-17.
21. Aaronson KD, Schwartz JS, Chen TM, Wong KL, Goin JE, Mancini DM. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplantation evaluation. Circulation 1997;95:2660-7.
22. 1-bridge to cardiac transplantation. Eur Heart J 1997;18:318-29.
23. 1-induced moderation of elevated pulmonary vascular resistance. Survival on waiting list and results of orthotopic heart transplantation. J Heart Lung Transplant 1993;12:173-8.
24. 1 in the pretransplantation period in patients with pulmonary hypertension. J Heart Lung Transplant 1993;12:884.
25. Delegado Jimenez JF, Gomez-Sanchez MA, Calle Perez G, et al. Pulmonary arterial hypertension and heart transplantation: hemodynamic evolution and survival. Rev Esp Cardiol 1996;49:804-9.
26. Lopez-Ciudad VJ, Perez LJM, Polanco FS, et al. Pulmonary hypertension and early mortality after orthotopic heart transplantation. Rev Esp Cardiol 1995;48:552-6.
27. Kirklin JK, Naftel DC, Kirklin JW, Blackstone EH, White-Williams C, Bourge RC. Pulmonary vascular resistance and the risk of heart transplantation. J Heart Transplant 1988;7:331.
28. Deng MC. Cardiac transplantation. Heart 2002;87:177-84.
29. Higenbotam TW, Butt AY, McMahon A, et al. Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart 1998;80:151-5.
30. Machherndl S, Kneussel M, Baumgartner M, et al. Long-term treatment of pulmonary hypertension with aerosolized iloprost. Eur Respir J 2001;17:8-13.
31. Michaelakis E, Tymchak W, Lien D, et al. Oral sildenafil is an effective and specific pulmonary vasodilatator in patients with pulmonary arterial hypertension: comparison to inhaled nitric oxide. Circulation 2002;105:2398-403.
32. Dietrich CG, Geier A, Lammert F. Bosentan for pulmonary hypertension. N Engl J Med 2002;347:292-4.
33. Adamson RM, Dembitsky WP, Jaski BE, et al. Left ventricular assist device support of medically unresponsive pulmonary hypertension and aortic insufficiency. ASAIO J 1997;43:365-9.
34. Auler Junior JO, Carmona MJ, Bocchi EA, et al. Low doses of inhaled nitric oxide in heart transplant recipients. J Heart Lung Transplant 1996;15:443-50.
35. Kozlov IA, Poptsov VN. Inhalation nitric oxide during heart transplantation. Anesteziol Reanimatol 1999;5:9-14.
36. Paniagua MJ, Crespo-Leiro MG, Rodriguez JA, et al. Usefulness of nitric oxide inhalation for management of right ventricular failure after heart transplantation in patients with pretransplant pulmonary hypertension. Transplant Proc 1999;31:2505-6.
37. Williams TJ, Salamonsen RF, Snell G, Kaye D, Esmore DS. Preliminary experience with inhaled nitric oxide for acute pulmonary hypertension after heart transplantation. J Heart Lung Transplant 1995;14:419-23.
38. 1 infusion for right ventricular failure after cardiac transplantation. J Thorac Cardiov Sur 1992;103:33-9.
39. Kawaguchi A, Gandjbakhch I, Pavie A, et al. Cardiac transplant recipients with preoperative pulmonary hypertension. Evolution of pulmonary hemodynamics and surgical options. Circulation 1989;80(111):90-6.
40. Tenderich G, Koerner MM, Stuettgen B, et al. Does preexisting elevated pulmonary vascular resistance (TPG > 15 mmHg or >5 Wood) predict early an long-term results after orthotopic heart transplantation? Transplant Proc 1998;30:1130-1.
41. Tenderich G, Koerner MM, Stuettgen B, et al. Pre-existing elevated pulmonary vascular resistance: long-term hemodynamic follow-up and outcome of recipients after orthotopic heart transplantation. J Cardiovasc Surg 2000;41:215-9.